Outcomes in Psoriasis Clinical Trials from January 2011 to March 2012

被引：0

作者：

Francesca Sampogna

Damiano Abeni

机构：

[1] Health Services Research Unit, Istituto Dermopatico dell'Immacolata IDI-IRCCS, 00167 Rome

来源：

Current Dermatology Reports | 2012年 / 1卷 / 3期

关键词：

Assessment; Clinical severity; Clinical trials; Dermatology; Dermatology Life Quality Index; DLQI; Outcomes; Palmoplantar psoriasis; PASI; PGA; Physician's Global Assessment; Plaque psoriasis; Plaque psoriasis of hands and feet; Psoriasis; Psoriasis Area and Severity Index; Psoriatic arthritis; Quality of life; Scalp psoriasis;

D O I：

10.1007/s13671-012-0019-5

中图分类号：

学科分类号：

摘要：

In clinical trials, conclusions on treatment safety and efficacy depend on the selected outcomes; therefore, it is very important to choose outcomes that are able to address meaningful aspects of the disease experience. This review analyzes 54 clinical trials of psoriasis treatments that took place from January 2011 to March 2012. The majority of the primary outcomes were based exclusively on the clinician/investigator assessment. Twenty-four percent of studies had a patient-reported measure listed as primary outcome. However, of the 34 studies reporting secondary outcomes, only seven had secondary outcomes based exclusively on the clinician/investigator assessment. Although there is a trend toward an increase in trials incorporating patient-reported measures, it is necessary to improve the quality of the measures used, and to adopt more thoroughly validated and homogeneous clinical measures and times of follow-up. © 2012 Springer Science+Business Media, LLC.

引用

页码：137 / 147

页数：10

共 67 条

[1]

Tugwell P., Boers M., Brooks P., Et al., OMERACT: an international initiative to improve outcome measurement in rheumatology, Trials, 8, (2007)

[2]

Sampogna F., Sera F., Abeni D., Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis, J Invest Dermatol, 122, 3, pp. 602-607, (2004)

[3]

Morsy H., Kamp S., Jemec G.B., Outcomes in randomized controlled trials in psoriasis: what has changed over the last 20 years?, J Dermatolog Treat, 18, 5, pp. 261-267, (2007)

[4]

Marks R., Barton S.P., Shuttleworth D., Finlay A.Y., Assessment of disease progress in psoriasis, Arch Dermatol, 125, 2, pp. 235-240, (1989)

[5]

Naldi L., Svensson A., Diepgen T., Et al., Randomized clinical trials for psoriasis 1977-2000: the EDEN survey, J Invest Dermatol, 120, 5, pp. 738-741, (2003)

[6]

Naldi L., Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? Facts and controversies, Clin Dermatol, 28, 1, pp. 67-72, (2010)

[7]

Sampogna F., Gisondi P., Melchi C.F., Et al., Prevalence of symptoms experienced by patients with different clinical types of psoriasis, Br J Dermatol, 151, 3, pp. 594-599, (2004)

[8]

Robinson A., Kardos M., Kimball A.B., Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis, J Am Acad Dermatol, 66, 3, pp. 369-375, (2012)

[9]

Tabolli S., Sampogna F., Pagliarello C., Et al., Disease severity evaluation among dermatological out-patients: a comparison between the assessments of patients and physicians, J Eur Acad Dermatol Venereol, 26, 2, pp. 213-218, (2012)

[10]

Townshend A.P., Chen C.M., Williams H.C., How prominent are patient-reported outcomes in clinical trials of dermatological treatments?, Br J Dermatol, 159, 5, pp. 1152-1159, (2008)

← 1 2 3 4 5 6 7 →